Lower circulating SHBG levels have been correlated with markers of metabolic dysregulation, suggesting its possible utility as a biomarker for hyperinsulinaemia, insulin resistance and metabolic dysfunction-associated steatosis liver disease (MASLD). Here, SHBG is linked to metabolic dysfunction-associated steatotic liver disease.